Europe
Opioid analgesics were associated with a 30% increase in the risk of pneumonia in persons with Alzheimer’s disease, a recent study from the University of Eastern Finland shows.
AstraZeneca underwent a restructuring earlier this year with an increased focus on oncology.
As the American Society of Clinical Oncology Annual Meeting winds down, here’s a look at some of Monday’s top stories.
AYOXXA Biosystems GmbH announces the launch of their next generation LUNARISTM Reader.
Rentschler Fill Solutions GmbH announced the appointment of Dr. Friedrich Sernetz as Chief Executive Officer (CEO). Dr. Sernetz’ appointment became effective as of June 1, 2019.
Lonza Group announced its intention to proceed with a carve-out of its Specialty Ingredients segment.
Biocartis Group NV, an innovative molecular diagnostics company, announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company.
Companies share robust oncology data at annual ASCO meeting.
Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.
Overall survival rates in the intent-to-treat population at 42 months for the Kisquali combination group was 70.2% compared to 46.0% for hormone therapy alone.
PRESS RELEASES